We use necessary cookies that allow our site to work. We also set optional cookies that help us improve our website. For more information about the types of cookies we use, visit our Cookies policy.

Cookie settings

Gilead Sciences

Gilead’s work to address neglected tropical diseases (NTDs) began over three decades ago when we launched our partnership with the World Health Organization (WHO) provide our therapy for the treatment of visceral leishmaniasis at a no-profit price in low- and middle-income countries where it is highly endemic. Moreover, in 2022 the WHO published guidelines that strongly recommend this medicine as part of the preferred regimen for the treatment of HIV-related cryptococcal meningitis. As a result, we expanded our global access program to include treatment of HIV-related cryptococcal meningitis as well.

Partner website

Become a partner

Whether you’re an individual or an organisation, there are ways you can join us and help to end neglected tropical diseases (NTDs).

Find out more